C4IP is a bipartisan coalition dedicated to promoting strong and effective IP rights that drive innovation, boost economic competitiveness, and improve lives.
๐ฃ C4IP today announced that Coke Morgan Stewart, a nationally recognized leader in IP law and policy and former @USPTO deputy director, has joined the organization as president and CEO.
Her appointment marks a new chapter for C4IP as it expands its reach and advocacy for strong and secure IP rights.
Read our full statement:
https://t.co/AbdZbcFTdK
In @FoxNews, former USPTO Deputy Director Coke Morgan Stewart makes the case for AI policy that supports both innovation and creativity:
"AI innovation is vital to America's future. But America's creative industries still depend on strong copyright protections. Policymakers need to promote both."
Read more โฌ๏ธ
https://t.co/txUWXyqPcv
The importance of innovation to the American people, our national security, and the continued growth of our economy cannot be overstated.
Yet, in several critical areas, U.S. innovation is at risk of falling behind.
Learn more about the current state of our innovation ecosystem:
https://t.co/IFItrNTPSz
"Patients want medical advances, and they want choices. If we demonize new versions of existing medicines, we won't just harm innovation, we will harm medical outcomes for the people who depend on them."
- Coke Morgan Stewart, C4IP President and CEO
Continue reading โฌ๏ธ
https://t.co/WYv3NHOzcE
The NSCEB report treats rising licensing deals with Chinese biotech firms as a warning sign for American innovation. But the number of licensing agreements tells us little about their impact on the U.S. biotech ecosystem.
Licensing can help American companies access and commercialize discoveries developed abroad, supporting U.S. innovation and competitiveness rather than ceding those opportunities to foreign competitors.
Policymakers should focus on domestic reforms to strengthen America's IP system and ensure American innovators can compete globally, not impose sweeping restrictions that could hurt America's competitiveness.
Learn more:
https://t.co/O084gfbFT5
Today, C4IP President & CEO Coke Morgan Stewart issued a statement in response to @HiTechInventors' irresponsible and misleading claim that the @USPTO granted more than 150,000 invalid patents in 2024.
Read our statement:
https://t.co/2CW0jkR5g2
โ Myth: Terminal disclaimers are used to prolong a patent owner's exclusivity.
โ Fact: A terminal disclaimer limits the enforceable life of the later patent rather than extending it.
For more myths and facts, check out our issue brief:
https://t.co/P9kemIVNv2
Intellectual property rights underpin scientific and technological advances, boosting America's economic competitiveness and improving lives across the globe.
That's why strong and effective IP rights are so important.
Reach out to your Senator or Representative and urge them to protect American innovation:
https://t.co/gSe4Bt2oyA
There is nothing unusual or malicious about filing multiple patents to protect different components of a single product.
In fact, being able to do so is vital to the development of high-tech products across all industries, from smartphones to medicines.
Obtaining multiple patents offers no unfair advantage to the patent owner, as all granted patents must comply with statutory requirements for patentability.
Learn more:
https://t.co/ki1OUHyVs3
Big Pharma is waging a war on generics. It's time to end it.
PCMA's new campaign exposes how drugmakers use patent thickets and other tactics to delay lower-cost generic and biosimilar competition and keep prescription drug prices high.
Watch the latest ad below and learn more at https://t.co/ZS7JnDd9Kb
In the News ๐๏ธ
C4IP Executive Director Frank Cullen was quoted in a Law360 article on the USPTO's proposal to limit PTAB challenges, expressing C4IP's support for the proposed rules and the PREVAIL Act.
Take a look:
https://t.co/pw7xT7gb4P
Patent pools are a time-tested approach to licensing standard-essential patents.
These collaborative arrangements allow implementers to conveniently obtain licenses to patents held by multiple owners through a single, standardized agreement.
To learn more about patent pools, check out our blog:
https://t.co/4vIfCsmQpk
ICYMI: Our "Idea Factories" webinar explored how strong IP protections sustain America's technology ecosystems.
Read our blog for a roundup of the key takeaways from the panelists:
https://t.co/mkBJK0CASk
We sent a letter to @JudiciaryDems@SenJudiciaryGOP ahead of the Committee's November 17 hearing on competition and transparency:
"We urge the Committee not to mistake weakening patent protections for lowering drug prices."
Continue reading:
https://t.co/Xi2FLXObt6
"Terminal disclaimers are not evidence that patent owners are somehow gaming the system in order to extend their exclusivity. In fact, their very purpose is to limit how long a later patent can last."
- C4IP Board Members and former Federal Judges Paul Michel and Kathleen O'Malley
Read more: https://t.co/A0IVtOpDvG
C4IP President & CEO Coke Morgan Stewart recently spoke at @uiclaw, calling on Washington to provide greater clarity and predictability for inventors and investors:
"I see a future where improvements to the patent system create clear, predictable, and enduring protections..."
More insights ๐
https://t.co/hW0c3k5lG1
In MLex's coverage of the GAO report on the USPTO's patent backlog reduction efforts, C4IP President & CEO Coke Morgan Stewart discusses the importance of supporting patent examiners and providing the office with the resources it needs to sustain its progress.
๐ฐ Take a look:
https://t.co/rnn9LzNNgV
"America's innovation leadership is itself a national security asset. We urge Treasury to distinguish transactions that pose genuine security risks from those that bring valuable intellectual property into American hands."
Read our full statement:
https://t.co/OWE34iAO2Y
IP rights are among America's most valuable strategic assets.
Yet, in recent decades, U.S. leaders have allowed them to erode. At the same time, China is increasingly embracing IP.
To remain competitive with China and protect its national security, America must preserve its IP advantage.
To learn more, read our latest blog post:
https://t.co/YNTvCyg9ln
In IPWatchdog, C4IP Chief Policy Officer and Counsel Jamie Simpson warns that the Medication Affordability and Patent Integrity Act could allow biomedical inventors to be stripped of important IP rights due to simple procedural missteps.
Take a look:
https://t.co/4AgvlVhJxx
Supporters of the ETHIC Act frame it as a way to reduce drug prices by preventing pharmaceutical companies from constructing so-called "patent thickets."
But those supporters are misunderstanding, or misconstruing, how the patent system works.
If enacted, the ETHIC Act would weaken patent rights, reduce incentives for subsequent innovation, and create harmful consequences for all IP-intensive industries.
For more info:
https://t.co/S43x7BZk9V
Lower drug prices and medical innovation don't have to be mutually exclusive.
In the third and final episode of our Red Tape series, @RSI's Wayne T. Brough explores how smarter patent reform can remove barriers to competition, lower prescription drug prices, and protect genuine innovation.
Watch the video here: https://t.co/azYYUiVqy7